Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $29.17 and traded as low as $26.45. Viking Therapeutics shares last traded at $26.80, with a volume of 3,466,272 shares traded.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the company. Morgan Stanley reiterated an "overweight" rating on shares of Viking Therapeutics in a research note on Tuesday, September 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Viking Therapeutics in a research report on Thursday, October 15th. Wall Street Zen lowered shares of Viking Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Sunday, October 4th. UBS Group began coverage on shares of Viking Therapeutics in a report on Wednesday, October 14th. They issued a "buy" rating and a $94.00 price objective on the stock. Finally, Barclays upgraded shares of Viking Therapeutics to a "strong-buy" rating in a research report on Tuesday, October 13th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $93.36.
Check Out Our Latest Report on Viking Therapeutics
Viking Therapeutics Price Performance
The firm has a market capitalization of $3.42 billion, a P/E ratio of -4.96 and a beta of 0.79. The business has a fifty day moving average of $29.17 and a 200-day moving average of $32.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 7.27 and a current ratio of 7.27.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its earnings results on Wednesday, October 28th. The biotechnology company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.49). During the same quarter in the previous year, the business posted ($0.81) earnings per share. On average, sell-side analysts forecast that Viking Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new stake in shares of Viking Therapeutics during the 2nd quarter worth about $241,458,000. ADAR1 Capital Management LLC acquired a new stake in shares of Viking Therapeutics in the 2nd quarter worth approximately $22,393,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Viking Therapeutics in the 2nd quarter worth approximately $20,699,000. Marshall Wace LLP boosted its holdings in shares of Viking Therapeutics by 1,027.2% in the third quarter. Marshall Wace LLP now owns 482,060 shares of the biotechnology company's stock valued at $15,715,000 after acquiring an additional 439,293 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Viking Therapeutics in the second quarter valued at approximately $15,910,000. Institutional investors own 76.03% of the company's stock.
Viking Therapeutics Company Profile
(
Get Free Report)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. Founded in 2012, it develops medicines for metabolic and endocrine disorders and does not have commercially marketed products. The company's pipeline includes VK2735, an investigational drug that targets the GLP-1 and GIP receptors and is being developed for obesity, and VK2809, a thyroid hormone receptor beta agonist being studied for metabolic and liver conditions. Viking is also developing VK0214 for X-linked adrenoleukodystrophy, a rare genetic disorder.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.